Clinical Impact of Noninvasive Plasma Microbial Cell-Free Deoxyribonucleic Acid Sequencing for the Diagnosis and Management of Pneumocystis jirovecii Pneumonia: A Single-Center Retrospective Study

Kap Sum Foong; Mojolaoluwa Mabayoje; Abeer AlMajali

doi:10.1093/ofid/ofac652

Clinical Impact of Noninvasive Plasma Microbial Cell-Free Deoxyribonucleic Acid Sequencing for the Diagnosis and Management of Pneumocystis jirovecii Pneumonia: A Single-Center Retrospective Study

Open Forum Infect Dis. 2022 Dec 2;9(12):ofac652. doi: 10.1093/ofid/ofac652. eCollection 2022 Dec.

Authors

Kap Sum Foong^{1

2}, Mojolaoluwa Mabayoje³, Abeer AlMajali^{2

3

4}

Affiliations

¹ Division of Geographic Medicine and Infectious Diseases, Tufts Medical Center, Boston, Massachusetts, USA.
² Section of Infectious Diseases, University of Illinois College of Medicine, Peoria, Illinois, USA.
³ Department of Medicine, University of Illinois College of Medicine, Peoria, Illinois, USA.
⁴ OSF St. Francis Medical Center, Peoria, Illinois, USA.

Abstract

We present 23 cases of Pneumocystis jirovecii pneumonia (PCP) diagnosed with commercially available noninvasive plasma microbial cell-free deoxyribonucleic acid (mcfDNA) assay. Our findings suggest that plasma mcfDNA testing resulted in positive clinical impact for the diagnosis and treatment of PCP and coinfections in 82.6% of cases.

Keywords: Karius; PCP; Pneumocystis jirovecii pneumonia; mcDNA; microbial cell-free deoxyribonucleic acid.